Apr 24 |
Sage Therapeutics Q1 2024 Earnings Preview
|
Apr 18 |
Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal
|
Apr 18 |
Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
Apr 18 |
Sage Therapeutics: Reassessing Investment Post Parkinson's Failure (Rating Upgrade)
|
Apr 17 |
Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data
|
Apr 17 |
BofA downgrades Sage to underperform, cites failed Parkinson's study
|
Apr 17 |
Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark
|
Apr 17 |
Sage’s cognition drug fails in Parkinson’s study
|
Apr 17 |
Sage drops after mid-stage setback for Parkinson’s disease candidate
|
Apr 17 |
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
|